AEON AEON Biopharma Inc. - Ordinary Shares - Class A

$AEON Lake Street raised the firm’s on Biopharma (AEON) to $2 from $1 and keeps a Buy rating on the shares after the company announced the outcome of its Type 2b meeting with FDA.

$AEON it’s coming ???⏱️⚠️👀Once biosimilarity is established, FDA may approve a biosimilar for additional indications of the reference product through scientifically justified extrapolation, without requiring separate clinical studies in each indicati

$AEON Aeon Biopharma is positioning itself as a groundbreaking innovator in the multi-billion-dollar neuroscience market and is poised for a pivotal breakthrough with its best-in-class BOTOX® biosimilar, ABP-450. Thanks to a masterfully executed balance sheet restructuring—which slashed debt by over 90%—and a fully funded cash runway extending well into 2027, this medical gem possesses the fundamental strength to disrupt the market from the bottom up and offer visionary investors monumental upside potential.

$AEON 40-50 % held by insiders for a reason. Will be at the conference today in NY seeking potential investors upon presenting.

$AEON needs to stay above .25 watching closely $QCLS patiently waiting for the boom $CNTB stay above a dollar, and could see another pump! $SOAR patiently waiting here too

$AEON Share price went up to 41.8 almost 42 cents today and then totally crashed. Cashless warrants totally destroyed the high share price gain earlier today.

$AEON The biggest positive from today's announcement is regulatory clarity, rather than approval itself. FDA hasn't blocked the 351(k) biosimilar strategy; it has agreed in principle to AEON's CMAP approach, allowed AEON to potentially leverage substantial existing human data, and AEON can now move forward toward the next FDA interaction. I expect more to come from the company soon! This could fast track things

$AEON an insider bought 1,150,000 shares less than a month ago. Look it up. No insiders selling the past 3 years. Insiders hold a very high 53% of the shares.

$AEON * AEON announced positive pilot forced-degradation results on Sept. 9 showing ABP-450 and Botox had comparable degradation behavior under thermal and oxidative stress. The company plans a formal multi-lot comparability study next. * That’s important because this is new scientific/comparability data, not just a promotional announcement. * No new reverse split announcement showed up in the current SEC/news check. * There are also warrants at $0.3221 and $0.3704, according to a recent ownership filing.

$AEON Bro you're the only one on this feed heavily pumping this. Makes you look desperate and delusional.

$AEON 😍AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

$AEON After today's investor conference should attract a whale or two to send this tomorrow next week.

$AEON Why is the share price only 34 or 35 cents now if this company has anything of value now or in the future?

$AEON ⚠️🤗🚀🫵🏼. The Company looks forward to feedback from its planned BPD Type 2b interaction with the FDA in the second half of 2026, which is expected to help inform the next phase of development for ABP-450, including clinical pharmacology and comparative clinical study requirements

$AEON $SPY $BIYA I can't be the only one that is noticing that day trading is basically dead. Absolutely nothing holds anymore!!

$AEON 💡 This news represents a fundamental milestone, as it virtually eliminates the company's greatest scientific risk—potential biological dissimilarity to the original BOTOX® product—using hard laboratory data.

$AEON Conference appearance: Management is presenting live today, Thursday, September 10, at the Lake Street BIG10 Conference in New York. September 9, 2026 (Last night): HIGHLIGHT: Announcement of highly successful pilot stability data (forced degradation) confirming a molecular structure identical to BOTOX®. Backed by this sensational laboratory data, AEON Biopharma is demonstrating to the entire medical community that its blockbuster candidate, ABP-450, is in no way inferior to the multi-billion-dollar original, BOTOX®! Driven by a top-tier leadership team of former FDA executives and rock-solid financing, this biotech gem is catapulting itself today from a state of extreme undervaluation straight to the top of global watchlists. 💡 This news represents a fundamental milestone, as it virtually eliminates the company's greatest scientific risk—potential biological dissimilarity to the original BOTOX® product—using hard laboratory data.

$AEON News of their study came yesterday morning, and the stock didnt move. Why is it moving now?

$AEON come here for entertainment only, most posts are bots or noise. Never ever ever take a decision based on anybody posting here.

$AEON sold long ago and back after a leave of absence. seems like an RS is a ways off. could be good to get back in